RÉSUMÉ
BACKGROUND: Hypogalactia and agalactia in lactating mothers are the major causes of child malnutrition, mortality, morbidity, and overall ill health. The development of such treatments requires a well-designed preclinical study with suitable laboratory animals, which needs to be improved. Thus, a suitably designed study with a laboratory animal to analyse galactagogue activity, along with an assessment of the quality and quantity of milk, is required. OBJECTIVES: This study aimed to evaluate the potential of rabbits as an animal model for studying lactogenic activity. METHODS: The structural homology of prolactin, prolactin, and prolactin in humans, rabbits, and rats was studied using BLAST and PyMol to assess similarity in the lactogenic system. Daily and cumulative milk production and pre-treatment (control) and post-treatment (three drugs) in rabbits were recorded and evaluated by analysing protein, fat, lactose, solid non-fat, and ash values. All parameters were recorded on the 0th day and at the end of weeks 1, 2, and 3. Mammary gland histopathology was performed to evaluate the effects on mammary glands. RESULTS: Homology studies revealed that the sequences of the human and rabbit prolactin genes, receptors, and hormones had a high similarity index. Treatment with Domperidone, Metoclopramide, and Shatavari significantly enhanced milk production by enhancing prolactin secretion; only Shatavari increased milk nutrition. Enlargement of the tubuloalveolar ducts of the mammary glands was observed. CONCLUSION: Our findings suggest that rabbits are robust, reproducible, ethically superior, and preclinically relevant animals for assessing lactogenic activity.
RÉSUMÉ
Theranostics, a method that combines targeted therapy and diagnostic imaging, has emerged as a viable route for enhancing cancer treatment, and hybrid nanoparticles (HNPs) are at the forefront of this field. Metallic, polymeric, lipid-based, and silica- based HNPs are studied for targeting and biocompatibility. Using HNPs, chemotherapeutic drugs, small interfering RNA, and therapeutic genes can be given precisely and controlled. This enhances therapeutic efficacy and reduces adverse effects. With fluorescence dyes, MRI contrast agents, and PET tracers, real-time therapy response monitoring is conceivable. A nano platform with therapeutic and diagnostic capabilities holds great promise for personalized medicine and precision oncology. The present study discusses HNPs' biocompatibility, stability, immunogenicity, and long-term biosafety, which are crucial to the clinical translation of cancer theranostics. Further, in this in- -depth investigation, we investigated the design, synthesis, and multifunctional activities of HNPs for use in cancer theranostics.
RÉSUMÉ
Alzheimer's disease (AD) is the most common neurodegeneration having non-effective treatments. Vaccines or monoclonal antibodies are two typical immunotherapies for AD. Due to Aß neurotoxicity, most of the treatments target its generation and deposition. However, therapies that specifically target tau protein are also being investigated. UB311 vaccine generates N-terminal anti-Aß antibodies, that neutralize Aß toxicity and promote plaque clearance. It is designed to elicit specific B-cell and wide T-cell responses. ACC001 or PF05236806 vaccine has the same Aß fragment and QS21 as an adjuvant. CAD106 stimulates response against Aß1-6. However, Nasopharyngitis and injection site erythema are its side effects. AN1792, the first-generation vaccine was formulated in proinflammatory QS21 adjuvant. However, T-cell epitopes are omitted from the developed epitope AD vaccine with Aß1-42B-cell epitopes. The first-generation vaccine immune response was immensely successful in clearing Aß, but it was also sufficient to provoke meningoencephalitis. Immunotherapies have been at the forefront of these initiatives in recent years. The review covers the recent updates on active and passive immunotherapy for AD.
Sujet(s)
Maladie d'Alzheimer , Vaccins contre la maladie d'Alzheimer , Peptides bêta-amyloïdes , Immunothérapie , Maladie d'Alzheimer/immunologie , Maladie d'Alzheimer/thérapie , Humains , Animaux , Immunothérapie/méthodes , Peptides bêta-amyloïdes/immunologie , Vaccins contre la maladie d'Alzheimer/immunologie , Vaccins contre la maladie d'Alzheimer/usage thérapeutique , Immunisation passive/méthodes , Anticorps monoclonaux/usage thérapeutique , Immunothérapie active/méthodesRÉSUMÉ
Nanoparticles have been crucial in redesigning tumour eradication techniques, and recent advances in cancer research have accelerated the creation and integration of multifunctional nanostructures. In the fight against treatment resistance, which has reduced the effectiveness of traditional radiation and chemotherapy, this paradigm change is of utmost importance. Graphene oxide (GO) is one of several nanoparticles made of carbon that has made a splash in the medical field. It offers potential new ways to treat cancer thanks to its nanostructures, which can precisely transfer genetic elements and therapeutic chemicals to tumour areas. Encapsulating genes, protecting them from degradation, and promoting effective genetic uptake by cancer cells are two of GO nanostructures' greatest strengths, in addition to improving drug pharmacokinetics and bioavailability by concentrating therapeutic compounds at particular tumour regions. In addition, photodynamic treatment (PDT) and photothermal therapy (PTT), which use GO nanoparticles to reduce carcinogenesis, have greatly slowed tumour growth due to GO's phototherapy capabilities. In addition to their potential medical uses, GO nanoparticles are attractive vaccine candidates due to their ability to stimulate cellular and innate immunity. These nanoparticles can be used to detect, diagnose, and eradicate cancer because they respond to certain stimuli. The numerous advantages of GO nanoparticles for tumour eradication are attributed in large part to their primary route of internalisation through endocytosis, which guarantees accurate delivery to target locations. The revolutionary potential of multifunctional nanostructures in cancer treatment is highlighted in this extensive compendium that examines current oncological breakthroughs.
Sujet(s)
Graphite , Immunothérapie , Tumeurs , Photothérapie , Graphite/composition chimique , Humains , Tumeurs/thérapie , Tumeurs/traitement médicamenteux , Photothérapie/méthodes , Animaux , Nanoparticules/composition chimique , Nanostructures/composition chimique , Vaccins anticancéreux/composition chimique , Vaccins anticancéreux/usage thérapeutique , Vaccins anticancéreux/immunologieRÉSUMÉ
AIM: Encapsulating epigallocatechin-3-gallate (EGCG) in pH-sensitive polymeric nanoparticles for targeted delivery of drugs could revolutionize colorectal cancer treatment. MATERIALS & METHODS: Nanoparticles were synthesized to release drugs at colon pH. Dynamic light scattering measured their average diameter and ζ-potential, while differential scanning calorimetry and x-ray diffraction assessed EGCG encapsulation. RESULTS: The nanoparticles showed stability and bioavailability in the gastrointestinal tract, efficiently encapsulating and releasing over 93% of EGCG at pH 7.2. They enhanced cytotoxicity against HT-29 cells and demonstrated antibacterial properties, increasing apoptosis and cell cycle arrest. CONCLUSION: The study underscores the potential of nanoparticles in enhancing EGCG delivery for colorectal cancer therapy, aiming to minimize side effects and improve therapeutic outcomes.
Sujet(s)
Apoptose , Catéchine , Tumeurs colorectales , Nanoparticules , Catéchine/analogues et dérivés , Catéchine/composition chimique , Catéchine/pharmacologie , Catéchine/administration et posologie , Humains , Tumeurs colorectales/traitement médicamenteux , Tumeurs colorectales/anatomopathologie , Concentration en ions d'hydrogène , Nanoparticules/composition chimique , Cellules HT29 , Apoptose/effets des médicaments et des substances chimiques , Vecteurs de médicaments/composition chimique , Antibactériens/composition chimique , Antibactériens/pharmacologie , Antibactériens/administration et posologie , Taille de particule , Libération de médicament , Survie cellulaire/effets des médicaments et des substances chimiquesRÉSUMÉ
Obesity and cancer have been found to have a direct link in epidemiological studies. Obesity raises the risk of cancer and associated chronic disorders. Furthermore, an imbalance of adipokines, like leptins, plays a crucial role in neoplasm pathogenesis, cell migration, and thereby, cancer metastasis. Also, leptin increases human epidermal growth factor receptor 2 (HER2) protein levels through the STAT3-mediated (signal transducer and activator of transcription) upregulation of heat shock protein (Hsp90) in breast cancer cells. It has been noticed that insulin and insulin-like growth factors (IGFs) act as mitosis activators in the host and cancerous breast epithelial cells. The condition of hyperinsulinemia explains the positive association between colorectal cancer and obesity. Furthermore, in prostate cancer, an alteration in sex hormone levels, testosterone and dihydrotestosterone, has been reported to occur, along with increased oxidative stress, which is the actual cause of the tumors. Whereas, there have been two interconnected factors that play a crucial role in the psychological cycle concerned with lung cancer. The review article focuses on all the prospects of etiological mechanisms that have found linkage with obesity and breast, colon, lung, and prostate cancers. Furthermore, the article has also highlighted how these new insights into the processes occur and, due to which reasons, obesity contributes to tumorigenesis. This review provides a detailed discussion on the progression, which can assist in the development of new and innovative techniques to interfere in this process, and it has been supported with insights based on evidence literature on approved clinical treatments for obesity and cancer.
Sujet(s)
Tumeurs du sein , Tumeurs de la prostate , Mâle , Humains , Leptine/métabolisme , Tumeurs du sein/épidémiologie , Tumeurs du sein/étiologie , Tumeurs du sein/métabolisme , Obésité/métabolisme , Adipokines , Tumeurs de la prostate/complications , TestostéroneRÉSUMÉ
Analytical quality by design and the use of dissimilar chromatographic systems can be employed to accelerate chromatographic separations. Herein, a software (S-Matrix)-assisted platform was used to proficiently screen, optimize and select the optimal parameters for the chromatographic separation of ketoconazole and its related impurities. This approach evaluated the various chromatographic parameters in a stepwise manner based on the statistical tools and provided an in-depth understanding of the critical parameters influencing the peak selectivities and separations. It was demonstrated that dissimilar conditions, such as different stationary phases, mobile phase pH and organic modifiers (i.e., critical method variables), can improve the peak resolution, while the critical quality attributes can provide conditions appropriate for quantification purposes via a quality target analytical method. Furthermore, an orthogonal method was established to support the primary method. The orthogonality between the two methods was defined by the correlation matrix between the two systems using the Pearson correlation coefficient and was found to be 0.12. Using the optimized method, the primary method was validated as per International Council for Harmonization in the range of 0.05-1.0% for impurities and 80.0-120.0% for ketoconazole, thereby indicating the suitability of the method for use in quality control laboratories.
RÉSUMÉ
Alzheimer's disease is a chronic lifestyle ailment whose occurrence has come to light with the increasing life expectancy due to better healthcare. The patient burden for AD is set to double by the year 2060 and advancement in research is of utmost importance to combat this problem. AD is characterized by the pathological hallmarks of amyloid plaques and neurofibrillary tangles. The disease has been implicated to have a genetic predisposition. The current treatment strategies are at best ameliorative in nature and offer no substantive cure. Immunotherapeutic approaches employed have shown few therapeutic benefits but the accelerated approval of aducanumab by the US-FDA shows clinical benefit merit. In addition, newer therapeutic approaches are the need of the hour. This review aims to highlight the pathology of the disease, followed by an insight into newer approaches like stem cell therapy and gene editing, focusing on possible CRISPR mediated targets.
Sujet(s)
Maladie d'Alzheimer/thérapie , Maladie d'Alzheimer/génétique , Maladie d'Alzheimer/immunologie , Animaux , Édition de gène/méthodes , Thérapie génétique/méthodes , Humains , Immunothérapie/méthodes , Transplantation de cellules souches/méthodesRÉSUMÉ
Objective: To investigate the effect of aloin against chronic constriction injury (CCI)-induced neuropathic pain in rats. Methods: Rats were randomly divided into 7 groups: Group Ⅰ (normal control), Group Ⅱ (sham-operated), Group Ⅲ (CCI control) and Group Ⅳ, Ⅴ, Ⅵ, and Ⅶ, which underwent CCI surgery and then were administered with aloin (5 mg/kg, p.o.; 25 mg/kg, p.o.; 125 mg/kg, p.o.) and gabapentin (50 mg/kg, p.o.), respectively for 14 days. Peripheral neuropathy was induced by silk ligatures (4-0) loosely placed around the sciatic nerve. Nociceptive thresholds against mechanical stimuli (Von-Frey filaments) and thermal stimuli (12 ℃ and 40 ℃) were measured at mid-plantar paw region ipsilateral to the compressed nerve on day-3, 7, 11, and 14. The concentration of cytokines including tumor necrosis factor-α (TNF-α), interleukin-6, and interleukin-1β was estimated at day-7. At day 14, motor nerve conduction velocity was determined under urethane anesthesia (1.25 g/kg). Oxidative stress parameters (malondiadehyde, glutathione, catalase, and superoxide dismutase) were estimated in sciatic nerve homogenates at day 14. Representative nerve samples were processed for histological investigations. Results: Aloin significantly reduced CCI-induced mechanical and thermal allodynia. It also improved motor nerve conduction velocity and decreased oxidative stress in nerve tissues. In addition, it decreased pro-inflammatory cytokine levels and restored the histoarchitecture of compressed sciatic nerve. Conclusions: Aloin mitigates CCI-induced neuropathic pain in rats by inhibiting oxidative stress and pro-inflammatory cytokines in the afflicted sciatic nerve.
RÉSUMÉ
Citrullus lanatus (Cucurbitaceae) is conventionally used for the treatment of urinary tract infection, renal stones, hypertension, diabetes and diarrhoea. Current study evaluates acute and 28 days repeated toxicity ethanolic extract of C. lanatus seed (EECLS) in Wistar rats to measure its safety profile. The single dose (2000 mg/kg BW) of EECLS was administered while in 28 days repeated study 250, 500 and 1000 mg/kg BW were administered orally in rats. Parameters such as biochemical, haematological and histopathological were analysed in subacute toxicity study. During study, no apparent sign of toxicity, behavioural changes and mortality were detected in acutely exposed animals. In 28 days repeated toxicity study, rats did not show significant changes in behaviour, gross pathology, body weight, biochemical and haematological parameters. Abridged serum glucose and cholesterol levels during the study designate their roles in treatment of hyperglycaemic and hyperlipidaemic conditions. No significant difference was observed in histopathology of liver and kidneys of treated rats. The current investigation demonstrated that EECLS is non-toxic below 1000 mg/kg BW and provides protection to some body organs. The data propose that LD50 of EECLS was greater than 2000 mg/kg BW and the no observed adverse effect level (NOAEL) of EECLS was at the dose of 1000 mg/kg in rats. Taken together, our finding suggests that, EECLS is safe and provides some protection to body organs; also, its extract can be used for further preclinical and clinical evaluation for its therapeutic activity.
Sujet(s)
Comportement animal/effets des médicaments et des substances chimiques , Poids/effets des médicaments et des substances chimiques , Citrullus/embryologie , Tests de chimie clinique/méthodes , Éthanol/composition chimique , Rein/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Extraits de plantes/toxicité , Graines/composition chimique , Animaux , Relation dose-effet des médicaments , Rein/anatomopathologie , Foie/anatomopathologie , Dose sans effet nocif observé , Extraits de plantes/administration et posologie , Rats , Rat Wistar , Tests de toxicité aigüeRÉSUMÉ
Lagenaria siceraria (Cucurbitaceae) is traditionally known to be used for the treatment of diabetes, ulcer, jaundice, cardiovascular disease, hemorrhoids, and colitis. This study involves evaluation of acute and subacute toxicity of methanolic extract of L. siceraria fruit (MELSF) in rats for assessment of its safety profile. For acute oral toxicity, single dose (2000 mg/kg body weight) of extract was administered in female Wister rats while in the subacute study the extract was given at doses of 250, 500, and 1000 mg/kg orally over 28 d in male and female rats. No evidence of toxicity was observed in animals when acutely exposed to MELSF, implying that the LD50 is higher than 2000 mg/kg body weight. Further, repeated administration of the extract for 28 d did not alter any hematological and biochemical parameters and no significant changes were observed in organ and body weight of control and treated groups. Histopathological assessment was normal in kidney and liver. Thus, the present investigation shows that MELSF, at dosage levels up to 1000 mg/kg, is nontoxic and can show protection of some body tissues when administered for 28 d and therefore can be considered safe. This study supports the application of L. siceraria in traditional medicine.
Sujet(s)
Cucurbitaceae/composition chimique , Extraits de plantes/toxicité , Administration par voie orale , Animaux , Relation dose-effet des médicaments , Femelle , Fruit , Dose létale 50 , Mâle , Méthanol/composition chimique , Extraits de plantes/administration et posologie , Rats , Rat Wistar , Tests de toxicité aigüe , Tests de toxicité subaigüeRÉSUMÉ
PURPOSE: Aloin, an anthraquinone present in the aloe species, possesses antiangiogenic, chemopreventive and antioxidant properties. It exerts cytotoxicity against breast cancer and ovarian cancer cell lines. These properties of aloin project it as a chemopreventive adjuvant to anticancer chemotherapy. METHODS: We evaluated the effect of concurrent oral administration of aloin against doxorubicin (DOX)-induced cardiotoxicity in rats. The protective effects of aloin against DOX-induced toxicity were evident as a statistically significant inhibition of a rise in the biochemical markers of myocardial damage including lactate dehydrogenase (LDH), creatinine kinase-myocardial band (CK-MB), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). RESULTS: Aloin dose dependently inhibited the DOX-induced changes in ECG like increased ST-height and prolonged QT interval. It protected heart against the lipid peroxidation and restored the levels of antioxidative defenses: reduced glutathione, catalase and superoxide dismutase. Aloin prominently reduced the levels of proinflammatory cytokines- TNF-α, IL-1ß and IL-6. Notably, the significant protective effects of aloin were evident even at the strikingly lower doses of 1 and 5 mg/kg per day. CONCLUSION: Our results highlight the necessity to further investigate the chemopreventive effects of aloin against other chemotherapeutic agents.
Sujet(s)
Cardiotoxicité/prévention et contrôle , Cytokines/métabolisme , Doxorubicine/effets indésirables , Émodine/analogues et dérivés , Médiateurs de l'inflammation/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Animaux , Antibiotiques antinéoplasiques/effets indésirables , Cardiotoxicité/étiologie , Cardiotoxicité/métabolisme , Cardiotoxicité/anatomopathologie , Cathartiques/pharmacologie , Émodine/pharmacologie , Mâle , Rats , Rat WistarRÉSUMÉ
Aloin exerts concentration-dependent pro-oxidant and antioxidant effects when tested in vitro. Such duality of effects has not been investigated through in vivo studies on aloin. We evaluated the effects of aloin at doses ranging between 1 and 125 mg/kg against the arsenic trioxide (As2O3)-induced cardiotoxicity in mice. As2O3 (5 mg/kg/day) was intraperitoneally administrated for 10 days. Aloin was administered through oral gavage at 1, 5, 25, and 125 mg/kg/day. As2O3 induced rise in ST height and QT interval in ECG, increased oxidative stress, and depleted the antioxidative defense. As2O3 increased inflammatory cytokine concentrations in the heart. Aloin dose dependently inhibited the As2O3-induced cardiotoxicity. There was no evidence of increased oxidative stress in the low-dose aloin-treated mice receiving As2O3. Our results indicate that aloin possesses cardioprotective potentials and its pro-oxidant effect is not evident in vivo at tested doses.
Sujet(s)
Anti-inflammatoires/pharmacologie , Trioxyde d'arsenic , Membrane cellulaire/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Émodine/analogues et dérivés , Cardiopathies/prévention et contrôle , Médiateurs de l'inflammation/métabolisme , Myocytes cardiaques/effets des médicaments et des substances chimiques , Animaux , Antioxydants/pharmacologie , Cardiotoxicité , Membrane cellulaire/métabolisme , Membrane cellulaire/anatomopathologie , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Émodine/pharmacologie , Cardiopathies/induit chimiquement , Cardiopathies/métabolisme , Cardiopathies/anatomopathologie , Mâle , Souris , Myocytes cardiaques/métabolisme , Myocytes cardiaques/anatomopathologie , Stress oxydatif/effets des médicaments et des substances chimiquesRÉSUMÉ
The use of cisplatin (CP) in chemotherapy of resistant cancers is limited due to its dose-dependent nephrotoxicity. Disulfiram (DSF), the aversion therapy for alcoholism, has recently emerged as an anticancer and chemopreventive agent. Its anticancer activity is potentiated in the presence of copper. However, such use of copper leads to several adverse effects. In the present study, the protective effect of DSF and its copper chelate (Cu-DEDC) against CP-induced nephrotoxicity in rats was evaluated. Nephrotoxicity was induced by a single intraperitoneal injection of CP (5 mg/kg). The treatment groups included control (vehicle treated), CP (CP-treated), CP + DSF (CP followed by DSF), CP + DSF + Cu (CP followed by DSF and CuCl2), CP + Cu-DEDC (CP followed by Cu-DEDC), and CP + AMF (amifostine pre-treated and CP-treated). The DSF, Cu-DEDC, and CuCl2 were administered orally at 50 mM/kg/day dose for 5 days post CP injection. AMF served as a standard chemo protectant, administered intravenously 30 min prior to CP. The markers of oxidative stress, inflammation, and kidney function estimated on the 6th day revealed that both DSF and Cu-DEDC significantly attenuated the CP-induced rise in the serum/urine creatinine and blood urea nitrogen (BUN). The CP-induced rise in serum alkaline phosphatase (ALPase) was reversed by these drugs. Both drugs reduced the levels of malondialdehyde and nitric oxide (NO) in kidney tissues. These drugs reversed CP-induced depletion of SOD, catalase, and GSH in the kidneys. There was a significant reduction in the CP-induced TNF-α and IL-1ß production along with prevention of histological alterations. Above observations indicate that DSF and Cu-DEDC may have significance as adjuvants to protect against CP-induced nephrotoxicity.
Sujet(s)
Cisplatine/effets indésirables , Cuivre/pharmacologie , Disulfirame/pharmacologie , Rein/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Insuffisance rénale , Animaux , Azote uréique sanguin , Cisplatine/pharmacologie , Créatinine/sang , Rein/anatomopathologie , Mâle , Rats , Rat Wistar , Insuffisance rénale/sang , Insuffisance rénale/induit chimiquement , Insuffisance rénale/traitement médicamenteuxRÉSUMÉ
Inflammation is one of the common events in the majority of acute as well as chronic debilitating diseases and represent a chief cause of morbidity in today's era of modern lifestyle. If unchecked, inflammation leads to development of rheumatoid arthritis, diabetes, cancer, Alzheimer's disease, and atherosclerosis along with pulmonary, autoimmune and cardiovascular diseases. Inflammation involves a complex network of many mediators, a variety of cells, and execution of multiple pathways. Current therapy for inflammatory diseases is limited to the steroidal and non-steroidal anti-inflammatory agents. The chronic use of these drugs is reported to cause severe adverse effects like gastrointestinal, cardiovascular, and renal abnormalities. There is a massive need to explore new anti-inflammatory agents with selective action and lesser toxicity. Plants and isolated phytoconstituents are promising and interesting sources of new anti-inflammatories. However, drug development from natural sources has been linked with hurdles like the complex nature of extracts, difficulties in isolation of pure phytoconstituents, and the yield of isolated compounds in minute quantities that is insufficient for subsequent lead development. Although various in-vivo and in-vitro models for anti-inflammatory drug development are available, judicious selection of appropriate animal models is a vital step in the early phase of drug development. Systematic evaluation of phytoconstituents can facilitate the identification and development of potential anti-inflammatory leads from natural sources. The present review describes various techniques of anti-inflammatory drug screening with its advantages and limitations, elaboration on biological targets of phytoconstituents in inflammation and biomarkers for the prediction of adverse effects of anti-inflammatory drugs. The systematic approach proposed through present article for anti-inflammatory drug screening can rationalize the identification of novel phytoconstituents at the initial stage of drug screening programs.
Sujet(s)
Anti-inflammatoires/pharmacologie , Découverte de médicament , Évaluation préclinique de médicament , Animaux , Produits biologiques/composition chimique , Produits biologiques/pharmacologie , Produits biologiques/usage thérapeutique , Marqueurs biologiques , Développement de médicament , Découverte de médicament/méthodes , Évaluation préclinique de médicament/méthodes , Humains , Inflammation/traitement médicamenteux , Inflammation/étiologie , Inflammation/métabolisme , Modèles animaux , Thérapie moléculaire ciblée , Composés phytochimiques/composition chimique , Composés phytochimiques/pharmacologie , Composés phytochimiques/usage thérapeutique , Transduction du signal/effets des médicaments et des substances chimiques , Résultat thérapeutiqueRÉSUMÉ
Luffa acutangula (Cucurbitaceae), a perennial plant grows mainly in India, Southeast Asia, China, Japan, Egypt, and other parts of Africa, it is widely used in the traditional Indian medicinal system to treat various health conditions. The plant has been used in jaundice, diabetes, hemorrhoids, dysentery, headache, ringworm infection, and leprosy. More than 50 chemical compounds have been isolated from a plant which mainly comprises flavonoids, anthraquinones, proteins, fatty acids, saponin triterpene, volatile components, and other phytoconstituents. Crude extract of plant and its isolated compounds possess broad pharmacological activities such as antidiabetic, hepatoprotective, antiulcer, anticancer, immunomodulatory, antihyperlipidemic, antioxidant, antimicrobial, CNS depressant, analgesic, and anti-inflammatory. The toxicological evaluation in preclinical studies reported safety of the plant for human consumption, but comprehensive evaluation in clinical studies is required. However, further investigation is necessary for transformation of experience based treatment of plant into evidence based information. Evaluation of pharmacological activity with indicative biomarkers will help to reveal the mechanism of action of chemical constituents of plant extract. The data from preclinical studies recommends clinical evaluation of safety and efficacy of the plant. The current paper summarizes up-to-date information about a review of the traditional uses, phytochemistry, pharmacological activities, and toxicology to highlight the future prospects of the plant.
RÉSUMÉ
Mercury toxicity is an emerging problem in the world as its concentration is rising continuously due to increased industrial, medicinal and domestic uses. Exposure to mercury represents a serious challenge to humans and other living biomes. The aim of the present study was to assess the protective effect of natural products as Zingiber officinale extract and its active compound (6-gingerol) against mercuric chloride-induced hepatorenal toxicity and oxidative stress in male rats. Male Sprague-Dawley rats (150±10g, n=6 per group) were administered HgCl2 (12µmol/kg, ip; once only) the treatment of Zingiber officinale Rosc. extract (ZO: 125mg/kg, po) and 6-gingerol (GG: 50mg/kg, po) for three days after 24h of HgCl2 administration. Acute HgCl2 administration altered various biochemical parameters, including transaminases, alkaline phosphatase, lactate dehydrogenase, bilirubin, gamma-glutamyl transferase, triglycerides and cholesterol, urea, creatinine, uric acid and blood urea nitrogen contents with a concomitant decline in protein and albumin concentration in serum. In addition, a significant rise in lipid peroxidation level with concomitant decrease in reduced glutathione content and the antioxidant enzymes activities of superoxide dismutase, catalase, glutathione reductase, glutathione peroxidase and glutathione-S-transferase after acute HgCl2 exposure. Results of the present investigation clearly showed that both treatments as Zingiber officinale extract and 6-gingerol provide protection against acute mercuric chloride-intoxication by preventing oxidative degradation of a biological membrane from metal mediated free radical attacks. Biochemical data were well supported by histopathological findings. In conclusion, natural products may be an ideal choice against oxidative damage induced by mercury poisoning.
Sujet(s)
Catéchols/pharmacologie , Alcools gras/pharmacologie , Rein/physiopathologie , Foie/physiopathologie , Chlorure de mercure II/toxicité , Stress oxydatif/effets des médicaments et des substances chimiques , Agents protecteurs/pharmacologie , Zingiber officinale/composition chimique , Animaux , Marqueurs biologiques/métabolisme , Catalase/métabolisme , Glutathion/métabolisme , Glutathione peroxidase/métabolisme , Glutathione reductase/métabolisme , Glutathione transferase/métabolisme , Rein/effets des médicaments et des substances chimiques , Rein/anatomopathologie , Peroxydation lipidique/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Tests de la fonction hépatique , Mâle , Rat Sprague-Dawley , Superoxide dismutase/métabolismeRÉSUMÉ
Cyclophosphamide (CYP) induced hemorrhagic cystitis is a dose-limiting side effect involving increased oxidative stress, inflammatory cytokines and suppressed activity of nuclear factor related erythroid 2-related factor (Nrf2). Thymoquinone (TQ), an active constituent of Nigella sativa seeds, is reported to increase the expression of Nrf2, exert antioxidant action, and anti-inflammatory effects in the experimental animals. The present study was designed to explore the effects of TQ on CYP-induced hemorrhagic cystitis in Balb/c mice. Cystitis was induced by a single intraperitoneal injection of CYP (200 mg/kg). TQ was administered intraperitoneally at 5, 10 and 20 mg/kg doses twice a day, for three days before and three days after the CYP administration. The efficacy of TQ was determined in terms of the protection against the CYP-induced histological perturbations in the bladder tissue, reduction in the oxidative stress, and inhibition of the DNA fragmentation. Immunohistochemistry was performed to examine the expression of Nrf2. TQ protected against CYP-induced oxidative stress was evident from significant reduction in the lipid peroxidation, restoration of the levels of reduced glutathione, catalase and superoxide dismutase activities. TQ treatment significantly reduced the DNA damage evident as reduced DNA fragmentation. A significant decrease in the cellular infiltration, edema, epithelial denudation and hemorrhage were observed in the histological observations. There was restoration and rise in the Nrf2 expression in the bladder tissues of mice treated with TQ. These results confirm that, TQ ameliorates the CYP-induced hemorrhagic cystitis in mice through reduction in the oxidative stress, inhibition of the DNA damage and through increased expression of Nrf2 in the bladder tissues.
Sujet(s)
Benzoquinones/usage thérapeutique , Cyclophosphamide/toxicité , Cystite/induit chimiquement , Cystite/traitement médicamenteux , Altération de l'ADN/effets des médicaments et des substances chimiques , Hémorragie/induit chimiquement , Hémorragie/traitement médicamenteux , Facteur-2 apparenté à NF-E2/métabolisme , Animaux , Altération de l'ADN/génétique , Fragmentation de l'ADN/effets des médicaments et des substances chimiques , Glutathion/métabolisme , Immunohistochimie , Mâle , Souris , Souris de lignée BALB C , Facteur-2 apparenté à NF-E2/génétique , Stress oxydatif/effets des médicaments et des substances chimiques , Superoxide dismutase/métabolisme , Régulation positive/effets des médicaments et des substances chimiques , Régulation positive/génétique , Vessie urinaire/effets des médicaments et des substances chimiques , Vessie urinaire/métabolisme , Vessie urinaire/anatomopathologieRÉSUMÉ
OBJECTIVES: The cytokine erythropoietin is the primary stimulator of erythropoiesis and recombinant human erythropoietin (rHuEPO), which is widely used in the treatment of anemia associated with advanced chronic kidney disease (CKD). Adverse cardiovascular outcomes have been observed during clinical trials of anemia correction with rHuEPO in CKD patients. We investigated the effects of short-term, high-dose treatment with rHuEPO on platelet reactivity and effects of aspirin on platelet reactivity in healthy rats. MATERIALS AND METHODS: Animals received three daily dose of rHuEPO (25 µg/kg s.c.). Platelets were isolated after 48 h of last dose of rHuEPO to study the arachidonic acid-induced platelet aggregation. Aspirin (75 mg/kg p.o.) was given to animals just before 1 h of isolation of platelets. RESULTS: In rats, treatment with rHuEPO increased platelet reactivity and platelet count. The increased platelet reactivity was paralleled by decreased time-to-occlusion (TTO) in arterial thrombosis model, and decreased bleeding time after tail transection in rats. Treatment with rHuEPO followed by single dose of aspirin showed significant reduction in TTO and bleeding time as compared with aspirin-treated group. CONCLUSIONS: These findings suggest that rHuEPO increases platelet reactivity and aspirin normalizes the hyper-reactive platelet and may reduce the cardiovascular events associated with rHuEPO in CKD patients.